Nuvectis Pharma, Inc. - NVCT STOCK NEWS

Nuvectis Pharma announced positive results for NXP900 in treating Group 4 Medulloblastoma, presented at SIOPE Brain Tumour Group. The study, conducted on a mouse model, showed that NXP900 significantly inhibited tumor growth and improved survival rates. With 40% of Medulloblastoma cases classified as Group 4, and considering the poor prognosis for these patients, Nuvectis emphasizes the therapeutic potential of NXP900 as a promising treatment option. The company is committed to advancing NXP900 to address this unmet medical need in pediatric oncology.

Nuvectis Pharma, a company specializing in innovative oncology treatments, announced that Ron Bentsur, its CEO, will present an overview at the H.C. Wainwright Global Investment Conference.

The event is scheduled for May 24, 2022, at 4:00 PM Eastern Time. A live webcast will be available for approximately 30 days.

Nuvectis's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in preclinical testing.

Nuvectis Pharma, Inc (NASDAQ: NVCT) reported its financial results for Q1 2022, highlighting advancements in their oncology pipeline. The company is currently conducting a dose escalation Phase 1 trial for NXP800, a Heat Shock Factor 1 pathway inhibitor, and progressing IND-enabling studies for NXP900, a SRC/YES1 kinase inhibitor. In February 2022, Nuvectis completed its IPO, raising $16 million in gross proceeds. As of March 31, 2022, cash reserves stood at $16.7 million, significantly up from $5.7 million at the end of 2021, despite a net loss of $2.9 million for the quarter.

Nuvectis Pharma (NASDAQ: NVCT) presented promising data on NXP900 at the AACR Conference, highlighting its potent SRC/YES1 inhibition and unique mechanism of action. The drug demonstrated significant efficacy against squamous cancer cell lines and showed potential to re-sensitize Tagrisso-resistant NSCLC cells. Ongoing IND-enabling studies aim to expedite clinical program initiation. This announcement reinforces Nuvectis's commitment to addressing unmet medical needs in oncology while broadening the potential applications for NXP900.

Nuvectis Pharma (NASDAQ: NVCT) recently highlighted findings from an oral presentation on its clinical candidate NXP800 at the AACR Conference, focusing on its role as a Heat Shock Factor 1 (HSF1) pathway inhibitor. The presentation emphasized NXP800’s potential in treating ovarian clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma, with ARID1a identified as a key patient selection biomarker. Ongoing Phase 1 trials and extensive preclinical studies are underway to identify additional target tumor types. Nuvectis is committed to advancing its clinical programs and sharing data later this year.

Nuvectis Pharma reported financial results for 2021, marking a significant year for the company. It completed an initial public offering in February 2022, raising $16.0 million in gross proceeds. Nuvectis initiated a Phase 1a clinical trial for its drug candidate NXP800 and reported promising preclinical data for NXP900, targeting triple-negative breast cancer. The company managed cash prudently, with $5.7 million in cash and equivalents by the end of 2021, and an operating loss of $12.9 million for the year.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that its drug candidates NXP800 and NXP900 will be presented at the 2022 American Association for Cancer Research Meeting. NXP800, an orally active HSF1 pathway inhibitor, will have an oral presentation on April 10, 2022. NXP900, a preclinical Src kinase inhibitor, will be featured in a poster presentation on April 12, 2022. NXP800 is currently in a Phase 1 clinical study, while NXP900 is undergoing IND-enabling studies to target various cancers. Both candidates aim to address serious conditions of unmet medical need in oncology.

Nuvectis Pharma announced that CEO Ron Bentsur will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:30 PM PT (5:30 PM ET). The conference will showcase the company's focus on innovative precision medicines for oncology. Nuvectis is developing NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in IND-enabling pre-clinical testing. More details can be found on their website.

Nuvectis Pharma (NASDAQ: NVCT) announced promising findings published in Cancer Research, showcasing the potent activity of NXP900, a selective SRC/YES1 kinase inhibitor, particularly in Triple Negative Breast Cancer (TNBC) models with Integrin-Linked Kinase (ILK) loss. The study confirms NXP900's superior efficacy compared to bosutinib and highlights its potential to address significant unmet medical needs in breast cancer treatment. Ongoing preclinical studies aim to identify additional cancers and complete IND-enabling studies in 2022.